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Objective: To identify new cut-off values beyond which patients can be considered as satisﬁed or as
responders through patient acceptable symptom state (PASS) and OMERACTeOARSI (Outcome Measures
in RheumatologyeOsteoarthritis Research Society International) set of responder criteria in total joint
replacement.
Methods: Secondary analysis of a 1-year prospective multicenter study of 861 patients, 510 with total
knee replacement (TKR) and 351 with total hip prosthesis (THR). Pain and function data were collected
by the reverse scoring option of the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC). PASS values were identiﬁed with the 25th centile estimation using an anchoring question
about satisfaction with actual symptoms. OMERACTeOARSI set of responder criteria was based on
a combination of absolute and relative change of pain, function and global patient’s assessment. Receiver
operating characteristic (ROC) analysis was used as a complementary approach.
Results: The values for PASSwere about 80 and 69 for pain and function in THR, while these values were 80
and 68whenusingOMERACTeOARSI criteria. Regarding TKR, PASS valueswere about 75 and 67 inpain and
functionwith both criteria. ROC values were slightly lower in all cases. PASS and OMERACTeOARSI values
varied moderately across tertiles of baseline severity.
Conclusion: With the provided data we can establish when a patient can be considered as satisﬁed/
responder in joint replacement. The scores achieved at 1 year were very similar according to both criteria.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Although total joint replacement (TJR) has proven to be an
effective procedure in terms of improvements in pain and function
evaluated bymeans of some patient’s reported outcomes as health-
related quality-of-life (HRQoL) instruments1, we actually do not
know what kind of patients can be classiﬁed as responders to the
treatment and/or what would be the cut-off points in the scores
which discriminate responders and non-responders patients. Into: A. Escobar, Unidad de
ntevideo, 18, 48013 Bilbao,
6306.
tza.net (A. Escobar).
s Research Society International. Pgeneral, studies measure baseline scores and post surgical scores at
some point in time, 6 months or 1 year, and compare the change in
scores that patients as a whole have undergone. Several question-
naires measure outcomes in TJR, but nearly all of them measure
pain and function. One of the existing problems is that results are
expressed as continuous data, which may not be useful for the
clinicians as they do not know how to interpret changes in the
follow-up period. More speciﬁcally, clinicians should know how
many patients have a satisfactory response to the administered
therapy. Therefore the problem is deﬁning what would be a success
in terms of HRQoL2.
There are new approaches to measure the patient’s response to
the medical treatments. Amongst these we have the OMER-
ACTeOARSI set of responder criteria for osteoarthritis (OA)3 and the
patient acceptable symptom state (PASS75)4. The ﬁrst one classiﬁesublished by Elsevier Ltd. All rights reserved.
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of absolute and relative changes of pain, function and global
patient’s assessment. The concept of PASS is based on wellbeing
or satisfaction with the actual symptoms and is deﬁned as the
value beyond which patients consider themselves well4. Although
OMERACTeOARSI (Outcome Measures in Rheumatologye
Osteoarthritis Research Society International) set of responder
criteria was developed for patients with OA who entered into
clinical trials, we believe that it could be applied to patients with
more severe stages of the disease, those requiring joint replace-
ment for example, given the fact that responder’s criteria are based
on both absolute and relative changes in the scores.
Regardingpatient reported outcomesbasedonHRQoLweshould
draw conclusions from two view points of view: ﬁrstly, score
changes in each dimension from baseline to some point in time, say
1-year post surgery; secondly, the level of the patient’s current
symptom perception. Patients can improve from their baseline
status, but their ﬁnal state might not be satisfactory for them.
The aim of the present studywas to determine the cut-off values
of the pain and function dimensions of the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) beyond
which patients can be considered as responders to TJR based on
satisfaction with symptoms (PASS) and the OMERACTeOARSI
criteria set at 1-year post surgical management. In addition, we
have calculated these cut-off points through receiver operating
curve characteristics (ROC) analysis. Finally, we have evaluated
whether the PASS is stable over three time periods.
Methods
This is a secondary analysis of a 1-year prospective study that
tookplace in 15hospitals; three inAndalusia, three in Canary Islands
and nine in the Basque Country (Spain). The Institutional Review
Boards of the participant Hospitals approved the study. All patients
received a letter informing them about the study and asking for
voluntary participation. We considered that patients who returned
their questionnaires agreed to participate in the study.
Consecutive patients who were to undergo primary TJR for knee
or hip OA between March 2005 and December 2006 were eligible
for the study. Patients were excluded if they had psychiatric
disorders that would compromise their ability to properly answer
the questionnaires. We developed data-collection questionnaires to
retrieve data from the medical records and directly from the
patients. In the main study, we sent the questionnaires to the
patients at baseline, a month before surgery, at 3, 6 and 12 months
post surgery.
For the purpose of this study, inclusion criteria were patients
with TJR due to OA, complete baseline data, 1-year measurements
of HRQoL questionnaire (WOMAC) and the items related to the
derivation of the OMERACTeOARSI criteria, and ﬁnally the
anchoring question about satisfaction with symptoms to calculate
PASS scores. All patients had unilateral TJR.
Questionnaire
Weused theWOMACquestionnaire that is a disease-speciﬁc, self-
administered questionnaire developed to study patients with hip or
knee OA5. It has a multidimensional scale made up of 24 items
grouped into three dimensions: pain (ﬁve items), stiffness (two
items), and physical function (17 items). We studied the pain and
function dimensions. We used the Likert version with ﬁve response
levels foreach item, representingdifferentdegreesof intensity (none,
mild, moderate, severe or extreme) scored from0 to 4. The datawere
standardized to a range of values from 0 to 100. According to recent
recommendations6 in this study we used the reverse option, where0 represents the worst status and 100 the best possible status. The
WOMAC has been translated and validated into Spanish7,8.
Statistical analysis
We used three different statistical methods to calculate cut-off
values. First, following the paper of Tubach et al.4, we used the
concept of PASS that was developed taking into account the opin-
ions from the patient. It was based on their opinion about “actual
satisfaction with their symptoms”. This question was “If you had to
be the rest of your life with the symptoms you have now, how
would you feel?” We used a Likert version with four response
levels: very satisﬁed, somewhat satisﬁed, somewhat dissatisﬁed
and very dissatisﬁed. Then patients who were “very satisﬁed” or
“somewhat satisﬁed” were considered as satisﬁed while consid-
ering the remainder as unsatisﬁed (Yes/No). This question has been
used as anchor to calculate cut-off values. As we used the reverse
option of WOMAC scores, where 0 represents the worst status and
100 the best possible status, we deﬁned the PASS as the 25th centile
of the ﬁnal score at 1 year instead of the 75th centile. The samewas
done to calculate PASS at 3 and 6 months.
Secondly, we used the OMERACTeOARSI set of responder
criteria3. This set is as follows: if the patient has an improvement in
pain or function 50% and absolute change 20 then, he is
a responder. If the patient does not reach these criteria but has an
improvement in at least two of the three following criteria he will
also be a responder: 1. Pain 20% and absolute change 10; 2.
Function 20% and absolute change 10; 3. Patient’s global
assessment of the disease 20% and absolute change 10. This
initiative used different tools to assess pain, functional disability
and global patient’s assessment. To measure pain and function, the
visual analog scale (VAS) and WOMAC dimensions were the tools
most used, while for global assessment the VAS and Likert scales
were the most often used.
In our study, pain and functionwere measured by eachWOMAC
dimension. Patient’s global assessment was measured by a ﬁve-
point Likert scale. To create the OMERACTeOARSI criteria
a change of one point was considered as a 20% global assessment
change. As with PASS, we have also used the 25th centile approach
for the ﬁnal score at 1 year.
We stratiﬁed cut-off values of PASS and OMERACTeOARSI scores
by baseline tertiles of severity in each dimension.
Finally, a ROC analysis was performed, using as a gold standard
patients’ satisfaction with symptoms (Yes/No). As optimal cut-off
value for the 1-year score of each dimension was considered the
one that maximized the sum of sensitivity and speciﬁcity. We draw
500 bootstrap samples, calculated their respective ROC curves and
derived a cut-off value for each. The cut-off values given are the
mean values of the 500 cut-off points and presented along with
their derived 95% conﬁdence interval (CI). This approach was used
to study the robustness of the cut-off values across both criteria,
PASS and OMERACTeOARSI.
Descriptive statistics included frequencies and percentages for
categorical variables and means and standard deviations (SD) for
continuous variables. Chi-square and Fisher’s exact tests were used
for comparing categorical variables, whereas the Student’s t test
was used for continuous variables.
Statistical analyses were performed using SPSS, v. 17 for
Windows (SPSS Inc) and Conﬁdence Interval Analysis (CIA) v.2.0.
Results
For the present secondary analysis there were 861 patients who
met all three inclusion criteria. Of those, 510 patients (59.2%) had
undergone knee replacement and 351 (40.8%) hip arthroplasty.
Table II
WOMAC scores at 1 year according to the different criteria and joints
WOMAC* dimensions Hip replacement
(n ¼ 351)
Knee replacement
(n ¼ 510)
Pain
PASSy, 25th centile (95% CIz) 80.0 (75.0e85.0) 75.0 (70.0e80.0)
ROC** curve (95% CI) 70.0 (69.4e70.6) 71.4 (71.1e71.8)
AUCyy (IC 95%) 0.77 (0.70e0.84) 0.83 (0.78e0.87)
OMERACTeOARSI, 25th
centile (95% CI)
80.0 (75.0e85.0) 75.0 (70.0e80.0)
Function
PASSy, 25th centile (95% CI) 69.1 (67.6e72.1) 67.7 (64.7e70.6)
ROC** curve (95% CI) 68.8 (68.4e69.3) 63.3 (62.9e63.6)
AUCyy (IC 95%) 0.81 (0.75e0.87) 0.83 (0.79e0.88)
OMERACTeOARSI, 25th
centile (95% CI)
67.6 (64.7e68.8) 66.2 (64.7e69.1)
PASSy responders
(satisﬁed), % (95% CI)
84.0% (80.2e87.8) 78.8% (75.3e82.3)
OMERACTeOARSI
responders, % (95% CI)
94.6% (92.2e97.0) 86.3% (83.3e89.3)
* Western Ontario and McMaster Universities Osteoarthritis Index. From
0 (worst) to 100 (best).
y Patient acceptable symptom state.
z Conﬁdence interval.
** Receiver operating characteristics curve.
yy Area under the curve, to study the discriminatory ability of the cut-off point
based on the ROC curve to predict PASS-responders.
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females and patients were older and more obese. Table I shows
baseline data and data at 1 year on the WOMAC dimensions. There
was no baseline difference between the two joints in the pain
dimension, but patients who had undergone hip replacement
reached better scores at 1 year (P < 0.001), so they had higher
improvement. Regarding the function dimension, although there
was baseline difference (P ¼ 0.001) between hip and knee joints,
the improvement at 1 year was also higher in patients undergoing
hip replacement (P < 0.001).
In Table II we can see the values of the WOMAC scores at 1 year
achieved by patients who fulﬁlled each criterion studied, PASS,
OMERACTeOARSI and the values that maximized sensitivity and
speciﬁcity through ROC and their corresponding CIs.
PASS
In patients considering their current state as satisfactory by PASS
anchoring question (84% for hip replacement and about 79% for
knee replacement), the cut-off points in the hip cohort for WOMAC
dimensions at 1 year based on 25th centile were 80 in the pain
dimension and about 69 in function. In the patients who had
undergone knee replacement these values were 75 points and 68,
respectively.
Responders by OMERACTeOARSI criteria
In the hip cohort about 95% of the patients were responders to
the OMERACTeOARSI criteria, and about 86% when considering
patients with knee replacement. When using the 25th centile
approach based on these responders patients, the scores at 1 year in
the patients with hip OAwere 80 points in pain and about 68 in the
function dimension. Regarding knee-operated patients, these cut-
off values were 75 in pain and 66 points in function.
ROC
Regarding the best cut-off points by ROC analysis in the pain
dimension at 1 year, these values were 70 and 71 in the hip and
knee patients, respectively. The values for WOMAC functional
dimension were about 69 and 63 points in hip and knee patients.
Considering these cut-off points, in all cases but pain in hip
replacement patients, the area under the ROC curve (AUC) was
higher than 0.80.
The estimates of the PASS and OMERACTeOARSI criteria strati-
ﬁed by baseline tertiles of severity are displayed in Table III.Table I
Patient’s characteristics and WOMAC dimension scores at baseline and at 1 year
Hip replacement Knee replacement P-value
n ¼ 351
Mean (SD)
n ¼ 510
Mean (SD)
Gender (females n%) 155 (44.3%) 349 (68.4%) <0.001
Age (years) 65.4 (12.5) 71.4 (6.9) <0.001
BMI* 28.0 (3.8) 30.4 (4.8) <0.001
WOMACy
Baseline pain 44.8 (17.4) 44.7 (18.6) 0.9
Pain at 1 year 84.6 (16.9) 78.7 (19.6) <0.001
Change in pain 39.8 (22.3) 34.0 (24.1) <0.001
Baseline function 35.1 (16.5) 39.0 (17.5) 0.001
Function at 1 year 75.9 (18.8) 71.8 (21.0) 0.003
Change in function 40.8 (21.7) 32.8 (23.8) <0.001
* Body mass index.
y Western Ontario and McMaster Universities Osteoarthritis Index. From
0 (worst) to 100 (best).Regarding pain, although the scores were very similar, from 70e75
to 80e85 points, the better the patient’s baseline score the higher
the cut-off value at 1 year in pain domain in both joints. These
differences between groups were around 5e10 points in both, the
PASS and OMERACTeOARSI criteria and in both joints. When
looking at the function dimension, this trend was clearer, from
about 60 points to 75 with differences of around 15 points between
those patients in the worst baseline situation and those in the
better situation. In the hip cohort, the percentage of satisﬁed
patients did not vary according to the baseline tertiles of pain
(P ¼ 0.9) or function (P ¼ 0.8). Regarding knee-operated patients,
there was a statistically signiﬁcant difference in the pain dimension
across baseline tertiles (P ¼ 0.04), but not in function (P ¼ 0.1).
Finally, Table IV lists the cut-off values with their 95% CIs over
time of WOMAC dimensions based on the 25th centile approach in
patients considering their current state as satisfactory by PASS
anchoring question. In general data of both dimensions were
similar at 6 months and 1 year. Likewise the percentage of patients
who considered themselves satisﬁed was about 82% in hip pros-
thesis and 77% in the knee replacement cohort. However, the
estimates corresponding to the ﬁrst evaluation carried out at
3 months post surgery were lower, both in the scores and in the
percentage of satisﬁed patients.Discussion
In this prospective study we applied the concepts of PASS, the
OMERACTeOARSI set of responder criteria on patients who have
undergone hip or knee replacement and to validate previous data,
we performed ROC analysis. The scores derived could be considered
as cut-off points for considering a patient as satisﬁed or responder
when performing TJR.
The concept of PASS represents an absolute value, not a change
and can be considered a clinical treatment target. PASS has been
deﬁned as the value beyond which patients can consider them-
selves well9 and has been widely used in rheumatology in several
diseases such as hip and knee OA4,10, rheumatoid arthritis11,
ankylosing spondylitis12, rotator cuff syndrome13 or Reynaud’s
phenomenon14 and recently in hip replacement15.
Table III
WOMAC scores at 1 year according to the PASS and OMERACTeOARSI criteria and joint divided into baseline severity tertiles
Low (worst) Hip replacement
(n ¼ 351)
High (best) Low (worst) Knee replacement
(n ¼ 510)
High (best)
Baseline tertiles Baseline tertiles
Medium Medium
WOMAC* dimension
Pain
Tertiles <40.0 40.1e54.9 >55.0 <35.0 35.0e54.9 >55.0
PASSy, 25th (95% CIz) 75.0 (70.0e85.0) 80.0 (75.0e85.0) 80.0 (75.0e85.0) 70.0 (65.0e75.0) 75.0 (70.0e80.0) 80.0 (75.0e85.0)
OMERACTeOARSI,
25th (95% CI)
75.0 (70.0e85.0) 80.0 (75.0e85.0) 85.0 (75.0e85.0) 70.0 (65.0e75.0) 75.0 (70.0e80.0) 85.0 (80.0e87.5)
PASSy responders
(satisﬁed), % (95% CI)
85.0% (78.5e91.5) 83.3% (76.5e90.1) 83.7% (77.0e90.4) 75.1% (68.6e81.6) 75.9% (69.5e82.3) 85.1% (79.7e90.5)
Function
Tertiles <26.5 26.5e42.5 >42.5 <32.0 32.0e45.5 >45.5
PASSy, 25th (95% CI) 60.1 (57.3e67.2) 72.1 (63.2e76.5) 75.0 (70.6e79.4) 60.3 (51.6e66.2) 67.7 (64.7e72.1) 72.8 (69.1e75.0)
OMERACTeOARSI,
25th (95% CI)
58.8 (54.4e62.5) 72.0 (63.2e75.0) 73.5 (69.1e76.5) 58.8 (52.9e63.2) 66.7 (63.2e69.1) 74.6 (70.6e76.5)
PASSy responders
(satisﬁed), % (95% CI)
82.5% (75.6e89.4) 85.6% (79.2e92.0) 84.2% (77.6e90.8) 75.0% (68.5e81.5) 83.8% (78.3e89.3) 78.9% (72.8e85.0)
* Western Ontario and McMaster Universities Osteoarthritis Index. From 0 (worst) to 100 (best).
y Patient acceptable symptom state.
z Conﬁdence interval.
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tive and absolute changes in scores. Although these criteria have
been used extensively in the literature to compare different inter-
ventions such as drugs16,17, dietary supplements18, medical
devices19,20 or the impact of rehabilitation programs21 to the best of
our knowledge this is the ﬁrst time they have been used after TJR to
establish cut-off values.
In this study we have used the reverse WOMAC scores, that is
from 0 (worst situation) to 100 points (best situation), so the
approach to the cut-off points corresponds to the 25th centile in
both criteria PASS and OMERACTeOARSI. Regarding ROC analysis
the cut-off point was that which maximized sensitivity and
speciﬁcity.
There were statistically signiﬁcant improvements in HRQoL
dimensions, pain and functionality for both joints. Although base-
line scores were similar in hip and knee patients those who
underwent hip replacement had higher improvements in both
dimensions at 1-year follow-up. This is a fact already reported in
the literature1,22e25. These higher improvements in both pain andTable IV
PASS scores estimate over time by joint
WOMAC* dimension Follow-up time
3 months 6 months 12 months
Hip
Pain, 25th
(95% CIy)
75.0 (70.0e80.0) 80.0 (75.0e81.2) 80.0 (75.0e85.0)
Function, 25th
(95% CIy)
63.2 (58.6e64.7) 67.6 (63.2e70.6) 69.1 (67.6e72.1)
PASS-responders
(satisﬁed),
% (95% CIy)
74% (69.4e78.6) 81% (76.9e85.1) 84% (80.2e87.8)
Knee
Pain, 25th
(95% CIy)
70.0 (65.0e75.0) 75.0 (70.0e80.0) 75.0 (70.0e80.0)
Function, 25th
(95% CIy)
63.9 (58.8e64.7) 64.7 (63.3e67.6) 67.7 (64.7e70.6)
PASS-responders
(satisﬁed),
% (95% CIy)
67.7% (63.6e71.8) 77% (73.3e80.7) 78.8% (75.3e82.3)
* Western Ontario and McMaster Universities Osteoarthritis Index. From
0 (worst) to 100 (best).
y Conﬁdence interval.function in patients undergoing hip replacement may explain the
higher percentage of patients who meet the criteria, whether
applying the PASS or considering the OMERACTeOARSI.
In the hip prosthesis cohort, the cut-off points at 1 year of the
pain dimension were similar in both criteria and a little lower
according to ROC. In the function dimension all three values were
similar. Likewise, the patients who had undergone knee replace-
ment had values nearly equal for pain according to the three
criteria. In the function dimension these values were again similar
in both criteria and a little lower according to ROC. The lower cut-
off values obtained by ROC analysis have been previously described
in other pathologies such as ankylosing spondylitis12 or rheuma-
toid arthritis11.
The higher percentages of satisﬁed patients measured by PASS
and responder patients by OMERACTeOARSI, in those who have
undergone hip replacement possibly agree with the greater
improvements that experienced these patients in both dimensions;
pain and function as measured by WOMAC. We should note that,
although in different ways, both approaches, PASS and OMER-
ACTeOARSI criteria are based on pain and function, PASS subjec-
tively and the other objectively. Our results agree with others
studies26 which have recently showed that 81% of patients claimed
that they were satisﬁed or very satisﬁed 1 year after total knee
replacement or that the patients with hip replacement had faster
and greater improvements than those with knee replacement23.
As in other studies4 our PASS estimates variedmoderately across
the tertiles of baseline severity. In this case also, values of both
criteria were quite similar in both joints within each tertile.
Although measured with other patient reported outcome, the
Oxford Hip Score15, our results at 1 year were similar and show that
the percentage of PASS responder patients did not vary according to
the baseline tertiles of severity in the hip cohort, neither in pain nor
in the function dimension. In patients with knee replacement there
were slight differences according to baseline tertiles of painwith the
higher percentage of PASS responder patients in the high baseline
tertile. Therefore, it appears that the cut-off values andpercentageof
satisﬁed patients can be considered independent of baseline scores.
Regarding stability over time, PASS values can be considered
stable from the 6th month onwards. This stability could be appli-
cable to the scores of both dimensions and to the percentage of
satisﬁed patients measured by the PASS concept.
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cohort studies, missing data can bias the results. When we
compared included patients with non-included (data not shown),
the observed statistically signiﬁcant differences were minor in
terms of points, in fact there were only differences of about three
and four points in baseline pain and function dimensions. No
differences regarding gender, age or body mass index (BMI) were
observed. Thus, although bias may be present by missing data it is
likely to be minor and we believe the results can be generalized.
Regarding OMERACTeOARSI criteria, there was a variable, the
patient’s global assessment, which can be measured on a VAS or
Likert scale. In our case, this itemwas measured by means of a ﬁve-
point Likert scale. To reproduce the original changes we considered
the 20% and absolute change 10 as one point in our scale. The
problem might be to consider this change as a measurement error
instead of a real change. On the other hand, the original authors
measured pain and function disability by VAS or WOMAC while we
used only WOMAC dimensions.
Another possible limitation is related to the PASS question.
There are two main differences with the original paper about
PASS4. First, the original question about patient’s opinion had
different wording and was recorded by answering “yes” or “no”
(Question: “Taking into account all the activities you carry out
during your daily life, your level of pain, and also your functional
impairment, do you consider that your current state is satisfac-
tory?). In our case the question, as cited above, was also focused
on satisfaction with symptoms but not as speciﬁc as in the orig-
inal. In addition the answers were rated on a four-point Likert
scale which was dichotomized as satisﬁed (very satisﬁed/satisﬁed)
and not satisﬁed (somewhat dissatisﬁed/very dissatisﬁed).
According to the OMERACT eight suggestions2, the issue of time
spent in the state was “rest of your life” given that it is assumed
that patients expect greater effects from surgery than from
medical therapy.
In conclusion, this study has provided data to know when
a patient can be considered as satisﬁed or a responder to the
treatment according to the PASS and OMERACTeOARSI criteria. The
scores achieved at 1-year post surgical management by the criteria
set are very close to those achieved by patients who considered
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